Sera Prognostics, Inc. has appointed Mark Capone to its Board of Directors, effective July 1, 2026. Mr. Capone brings over 40 years of experience in diagnostics, life sciences, biotechnology, medical devices, and pharmaceuticals. He has served as CEO of Myriad Genetics, transforming it into a precision medicine leader with significant revenue and employee growth. Mr. Capone will also join the Compensation Committee of the Board. He will receive standard compensation for non-employee directors, including equity awards (stock options and RSUs) and cash compensation. The initial equity award on July 10, 2026, will have a grant date fair value of $167,072 or 150,000 option equivalents. Subsequent annual equity awards will have a grant date fair value of $88,359 or 75,000 option equivalents. Mr. Capone is considered an independent director under Nasdaq and SEC guidelines. A press release announcing the appointment was issued on June 30, 2026.